Open Accessibility Menu

Coronavirus (COVID-19) Update - We are open with your safety in mind. Click here to learn more.

For information about COVID-19, the vaccine, or to view additional resources, please click here.

Psoriasis Clinic

Treating Patients throughout Virginia, Maryland & The U.S.

The Psoriasis Clinic at The GW Medical Faculty Associates is directed by Dr. Alison Ehrlich M.D, M.H.S. The clinic is highly regarded for its expertise with all types and severities of psoriasis. We treat patients from the Washington DC, Maryland, & Virginia region and from around the United States. Psoriasis is an inflammatory skin disease that tends to be chronic in nature. It is thought to be influenced by hereditary factors, although the specifics have yet to be determined. Psoriasis occurs in 1 to 2 percent of all Americans; the frequency of this condition varies amongst different ethnic groups. Both sexes are equally affected.

Psoriasis can occur at any age. It most typically develops for the first time in patients in their late teens or early twenties. A second time period of onset of this disease occurs when patients are in their late fifties. People with psoriasis develop a rash that can be very uncomfortable. Red plaques can develop that may be intensely itchy or painful. Psoriasis can also be associated with other medical conditions such as arthritis. We try to coordinate care of both skin and joints in patients by joint management of patients by both dermatology and rheumatology

Our Treatments

The Psoriasis Clinic offers a broad range of therapeutic modalities to treat this disease depending upon the severity of the illness. These include treatments such as:

  • Topical therapies
  • Systemic therapy including:Methotrexate, cyclosporine, retinoids (vitamin A derived medications)
  • Biologics: Enbrel®, Humira, Remicade®, Stelara®
  • Phototherapy: Narrow Band UVB and PUVA
  • Excimer Laser

There are many treatments for psoriasis that will potentially put your psoriasis into remission for long periods of time. At the present time there is no known cure for this condition. Sometimes psoriasis lesions can be treated with medication that is applied topically to the skin. For those with more extensive psoriasis, ultraviolet light treatments can be administered. Phototherapy treatment offers customized and intensive treatment of psoriasis warranted by the patient’s severity of disease. Various biologic agents are also utilized in patients with more severe cases.

In addition to offering this broad range of therapeutic approaches, patients may be able to access new investigational agents being studied by our Clinical Research Department. If you are interested in learning more about this, please contact our Clinical Research Department at (202) 677-6160.

Our clinic works closely with other specialists and internists to improve the overall health of psoriasis patients. Because psoriasis patients have an increased risk of cardiovascular disease and metabolic syndrome, we believe that it is important to work toward improving not only the skin but also our patients’ overall health.

Conveniently Located
News & Information
  • HS Scar Prevention Secrets That Really Work (

    Dr. Adam Friedman , Professor and Interim Chair of the Department of Dermatology at The GW Medical Faculty Associates, and Dr. Pooja Sodha , Director of the GW Laser Center , provide ...

    Read Full Article
  • Sweating Can Help Spread Covid-19, But Not By ‘Infectious Sweat’ (

    Dr. Adam Friedman , Professor and Interim Chair of the Department of Dermatology at The GW Medical Faculty Associates, comments on whether sweat can spread COVID-19. Read the full article on ...

    Read Full Article

Clinical Trials

  • Prurigo Nodularis (Chronic Prurigo)
    This study is a 12-month, observational, non-interventional study assessing biomarkers, clinical outcomes, and treatment-responsiveness in patients with prurigo nodularis (PN).Patients must be 18 years or older with a confirmed diagnosis of PN (with predominantly nodular disease) by the PI. They must be able to read and understand the consent form and outcomes questionnaires and willing and able to sign the consent form. A separate consent form will be used for genomics testing, which is encouraged for all study participants but not required. Lastly, patients must be willing to participate in the following study-related activities:1) Completion of outcome questionnaires2) Actigraphy data collection3) Biomarker collection by blood draws at each monthly study visit4) Skin biopsy collection5) Medical photography (8-24 photos taken each visit)
  • Photodynamic Therapy for Papulopustular Rosacea
    Dermatology at The GW Medical Faculty Associates is conducting an experimental research study to examine the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in treating rosacea. The purpose of this study is to evaluate if using 5-ALA PDT improves rosacea symptoms. We are seeking individuals with rosacea between the ages of 18 and 79 to volunteer to participate in this study. This study will take a total of six months (six total visits to the MFA). Prior to each visit, you will be examined and fill out a questionnaire. Participation in the study will be of no direct cost to you. If you are interested in participating in this research study, please contact Dermatology atThe GW Medical Faculty Associates.
    The goal of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis (AD). The dose-response of lebrikizumab in patients will also be measured. Patients with moderate-to-severe AD will be enrolled into this 32-week study. Patients will be seen every 2 weeks, will receive all study drug injections in the clinic, and be evaluated for safety and efficacy through Week 16. A safety follow-up visit will occur at Week 24 and a follow-up phone call will occur at Week 32.
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis
    The goal of this study is to evaluate the efficacy and safety of baricitinib 1-mg daily and 2-mg daily in comparison to placebo in adult patients with moderate to severe atopic dermatitis. The study is divided into 3 periods: a 5-week Screening Period, a 104-week Double-Blinded Treatment Period, and a 4-week Post-Treatment Follow-Up Period.
  • A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Active Cutaneous Lupus Erythematosus.
    The goal of this study is to evaluate the efficacy of BIIB059 in reducing disease activity in subjects with active cutaneous lupus erythematosus (CLE). The subject screening period will last up to 4 weeks. This will be followed by a treatment period of 16 weeks, with subjects randomized to 1 of 4 possible arms, all which will receive monthly treatments given in the office. Two groups will receive BIIB059 and two groups will receive the placebo. The following safety follow-up period will consist of 12 weeks of monthly visits.
  • Topical collagen powder as a wound healing adjuvant for acute full-thickness punch biopsy-induced human wounds: a pilot study
    The GW Medical Faculty Associates Department of Dermatology is conducting an experimental research study to assess collagen powder in treating acute wounds. The purpose of this study is to see if Nuvagen‚Ñ¢ (collagen powder) is effective in treating skin punch biopsy wounds. We are seeking healthy individuals between ages 18-75 to volunteer to participate in this study. The study will take a total of 12 weeks, including 6 total visits to the dermatology clinic. You will receive 1 punch biopsy on each thigh at the 1st and 4th visits. You will also be asked questions about your medical history, answer surveys, and have photographs taken. Participation in the study will be of no direct cost to you.